{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:10:43Z","timestamp":1784268643427,"version":"3.55.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a biologically heterogeneous immune-mediated disease characterized by substantial variability in therapeutic response. Despite the availability of multiple conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), many patients fail to achieve adequate disease control or experience secondary loss of efficacy, underscoring the need for predictive biomarkers that can guide treatment selection. This narrative review was based on a structured literature search of PubMed\/MEDLINE, Scopus, Web of Science, and Google Scholar, covering publications from January 2000 to June 2026, with earlier landmark studies included when relevant. Literature selection followed PRISMA-informed principles, although the review was not designed as a formal systematic review. Unlike previous reviews that mainly catalogue RA biomarkers by analytical platform, drug class, or clinical use, this review integrates conventional and emerging biomarkers within a tissue-immunophenotype-centered framework. We critically evaluate clinical, serological, pharmacological, molecular, imaging, and tissue-based biomarkers according to biological plausibility, reproducibility, level of validation, clinical actionability, and translational readiness. Established markers such as rheumatoid factor, anti-citrullinated protein antibodies, acute-phase reactants, drug concentrations, and anti-drug antibodies remain clinically useful but provide incomplete insight into mechanism-specific therapeutic response. In contrast, synovial pathotypes, fibroblast and macrophage subsets, B-cell niches, tertiary lymphoid structures, single-cell and spatial omics, and ligand\u2013receptor interaction networks offer a mechanistically richer view of treatment response and resistance. We conclude that precision medicine in RA will require integrated biomarker panels combining clinical, pharmacological, molecular, and synovial tissue data. The key future direction is the development of scalable, externally validated, and clinically interpretable models capable of assigning synovial endotypes and supporting mechanism-based therapeutic selection.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1880487","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:45:18Z","timestamp":1784267118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers of treatment response in rheumatoid arthritis: from conventional markers to tissue immunophenotype"],"prefix":"10.3389","volume":"17","author":[{"given":"N.A.","family":"Batashkov","sequence":"first","affiliation":[{"name":"Federal State Budgetary Scientific Institution \u201cFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies\u201d","place":["Moscow, Russia"]},{"name":"Moscow Center for Advanced Studies","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"Gerasimova","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution \u201cV.A. Nasonova Research Institute of Rheumatology\u201d","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Gerasimova","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.V.","family":"Svetlichnyy","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Petryakina","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.I.","family":"Tychinin","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Yudin","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.S.","family":"Yudin","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Keskinov","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency (Centre for Strategic Planning, of the Federal Medical and Biological Agency)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Bogdanov","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution \u201cFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies\u201d","place":["Moscow, Russia"]},{"name":"Moscow Center for Advanced Studies","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Zotkin","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution \u201cV.A. Nasonova Research Institute of Rheumatology\u201d","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Lila","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution \u201cV.A. Nasonova Research Institute of Rheumatology\u201d","place":["Moscow, Russia"]},{"name":"Moscow Clinical Scientific Center N.A. A.S. Loginov","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.V.","family":"Tabakov","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution \u201cFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies\u201d","place":["Moscow, Russia"]},{"name":"Moscow Center for Advanced Studies","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Woroncow","sequence":"additional","affiliation":[{"name":"Moscow Center for Advanced Studies","place":["Moscow, Russia"]},{"name":"Russian Medical Academy of Continuous Professional Education of the Ministry of Health Care of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.I.","family":"Skvortsova","sequence":"additional","affiliation":[{"name":"Lomonosov Moscow State University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.Yu","family":"Volchkov","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Scientific Institution \u201cFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies\u201d","place":["Moscow, Russia"]},{"name":"Moscow Center for Advanced Studies","place":["Moscow, Russia"]},{"name":"The Federal Medical Biological Agency (FMBA of Russia)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2025.102036","article-title":"A review on the epidemiology of rheumatoid arthritis: an update and trends from current literature","volume":"39","author":"Uke","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/ar1339","article-title":"No title found","volume":"6","author":"Kasperkovitz","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac114","article-title":"Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search","volume":"61","author":"Roodenrijs","year":"2022","journal-title":"Rheumatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-023-01129-2","article-title":"Synovial tissue insights into heterogeneity of rheumatoid arthritis","volume":"26","author":"Jonsson","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.23098","article-title":"Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies","volume":"6","author":"Bitoun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13075-020-2137-y","article-title":"Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis","volume":"22","author":"Yokoyama-Kokuryo","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.08.003","article-title":"Community health workers improve linkage to hypertension care in Western Kenya","volume":"74","author":"Vedanthan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.102019","article-title":"Global RA treatment recommendations: an update from the various international societies","volume":"39","author":"Cubberley","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1515\/rir-2024-0028","article-title":"Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update","volume":"5","author":"Tian","year":"2025","journal-title":"Rheumatol Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis: secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Modern Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"B15","article-title":"Biomarkers in rheumatoid arthritis, what is new","volume":"9","author":"Gavril\u0103","year":"2016","journal-title":"J Med Life"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.11.003","article-title":"Reliability of joint count assessment in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Cheung","year":"2014","journal-title":"Semin Arthritis Rheumatism"},{"key":"B17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","article-title":"Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition","volume":"19","author":"Schoels","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209429","article-title":"Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheumatic Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex211","article-title":"Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients","volume":"56","author":"Ferreira","year":"2017","journal-title":"Rheumatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004744","article-title":"Persistently different patterns of patient\u2019s global assessment of health in rheumatoid arthritis are associated with pain and impaired function more than with inflammation: an inception cohort study over 15 years","volume":"11","author":"Bala","year":"2025","journal-title":"RMD Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41569-020-0431-7","article-title":"Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6","volume":"18","author":"Tyrrell","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"B23","article-title":"Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis","volume":"30","author":"Combe","year":"2003","journal-title":"J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2022.2052626","article-title":"Biomarkers for the diagnosis and treatment of rheumatoid arthritis \u2013 a systematic review","volume":"135","author":"Abdelhafiz","year":"2023","journal-title":"Postgrad Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/ar4469","article-title":"Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year","volume":"16","author":"Kay","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140628","article-title":"Calprotectin as a biomarker for rheumatoid arthritis: a systematic review","volume":"42","author":"Abildtrup","year":"2015","journal-title":"J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","article-title":"Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis","volume":"22","author":"Jarlborg","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001025","article-title":"From bench to bedside: calprotectin (S100A8\/S100A9) as a biomarker in rheumatoid arthritis","volume":"13","author":"Inciarte-Mundo","year":"2022","journal-title":"Front Immunol"},{"key":"B29","article-title":"Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation","volume":"34","author":"Kilani","year":"2007","journal-title":"J Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13075-020-2110-9","article-title":"Tumour necrosis factor alpha promotes secretion of 14-3-3\u03b7 by inducing necroptosis in macrophages","volume":"22","author":"Trimova","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143529","article-title":"Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR\/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets","volume":"71","author":"De Launay","year":"2012","journal-title":"Ann Rheumatic Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics16020330","article-title":"Biomarkers in rheumatoid arthritis: from traditional serology to precision medicine integration","volume":"16","author":"Soyfoo","year":"2026","journal-title":"Diagnostics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-015-0799-7","article-title":"Serum 14-3-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab","volume":"17","author":"Hirata","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.3426","article-title":"SAT0070 levels of 14-3-3Eta predict good EULAR response to anti-TNF treatment in patients with rheumatoid arthritis","volume":"73","author":"Marotta","year":"2014","journal-title":"Ann Rheumatic Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060635","article-title":"Development of a multi-biomarker disease activity test for rheumatoid arthritis","volume":"8","author":"Centola","year":"2013","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae242","article-title":"Association of the multi-biomarker disease activity score with arterial 18-fluorodeoxyglucose uptake in rheumatoid arthritis","volume":"64","author":"Giles","year":"2025","journal-title":"Rheumatology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.21739","article-title":"The HLA\u2013DRB1 shared epitope alleles are primarily a risk factor for anti\u2013cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis","volume":"54","author":"Van Der Helm\u2010van Mil","year":"2006","journal-title":"Arthritis Rheumatism"},{"key":"B38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrrheum.2016.200","article-title":"Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis","volume":"13","author":"Catrina","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheumatic Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-018-1520-4","article-title":"Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes","volume":"20","author":"De Moel","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114465108","article-title":"Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage","volume":"108","author":"Shi","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/art.40237","article-title":"Association of the presence of anti\u2013carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR cohort","volume":"69","author":"Truchetet","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208870","article-title":"The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor","volume":"76","author":"Ajeganova","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2019-001249","article-title":"Elevated levels of anti-carbamylated protein antibody in patients with rheumatoid arthritis: association with disease activity and bone destruction","volume":"68","author":"Zhang","year":"2020","journal-title":"J Invest Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216709","article-title":"Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease","volume":"79","author":"Castellanos-Moreira","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12891-017-1563-8","article-title":"Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients","volume":"18","author":"Spinelli","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/g8xqxr","article-title":"Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept","volume":"39","author":"Kumar","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","volume":"110","author":"Van Delft","year":"2020","journal-title":"J Autoimmun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/acr2.11630","article-title":"Anti\u2013peptidylarginine deiminase 4 autoantibodies and disease duration as predictors of treatment response in rheumatoid arthritis","volume":"6","author":"Cappelli","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaf082","article-title":"The prediction of response to treatment using power Doppler in rheumatoid arthritis: a systematic review","volume":"9","author":"Gazel","year":"2025","journal-title":"Rheumatol Adv Pract"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004269","article-title":"Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study","volume":"10","author":"Mouterde","year":"2024","journal-title":"RMD Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022185","article-title":"Superb microvascular imaging evaluating joint lesion scores in rheumatoid arthritis compared with power Doppler imaging: a meta-analysis [RETRACTED","volume":"99","author":"Lin","year":"2020","journal-title":"Medicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-025-03706-5","article-title":"Microvascular imaging is superior to power Doppler in synovitis vascular flow detection in rheumatoid arthritis using the OMERACT-EULAR scoring system","volume":"28","author":"Madruga Dias","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219302","article-title":"Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study","volume":"80","author":"Matthijssen","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-022-04238-8","article-title":"Towards a simplified fluid-sensitive MRI protocol in small joints of the hand in early arthritis patients: reliability between modified Dixon and regular Gadolinium enhanced TSE fat saturated MRI-sequences","volume":"52","author":"Boeren","year":"2023","journal-title":"Skeletal Radiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220884","article-title":"EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis","volume":"80","author":"Mankia","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf149","article-title":"Do MRI-detected erosions in the RA-risk phase of arthralgia reflect current or imminent radiographic erosions? A large longitudinal imaging study","volume":"64","author":"Dumoulin","year":"2025","journal-title":"Rheumatology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-023-01896-z","article-title":"Role of PET\/CT in diagnosing and monitoring disease activity in rheumatoid arthritis: a review","volume":"38","author":"Singh","year":"2024","journal-title":"Ann Nucl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/rheumatology\/keab664","article-title":"Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy","volume":"61","author":"Dorst","year":"2022","journal-title":"Rheumatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/cpt.2974","article-title":"Methotrexate polyglutamates exposure \u2013 response modeling in a large cohort of rheumatoid arthritis patients starting methotrexate","volume":"114","author":"Hebing","year":"2023","journal-title":"Clin Pharma Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev356","article-title":"Biologic efficacy optimization\u2014a step towards personalized medicine","volume":"55","author":"Kiely","year":"2016","journal-title":"Rheumatology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/art.39946","article-title":"Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: A systematic review","volume":"69","author":"Tweehuysen","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00845","article-title":"A pauci-immune synovial pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients","volume":"11","author":"Nerviani","year":"2020","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001949","article-title":"Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis","volume":"8","author":"Micheroli","year":"2022","journal-title":"RMD Open"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0667-5","article-title":"NicheNet: modeling intercellular communication by linking ligands to target genes","volume":"17","author":"Browaeys","year":"2020","journal-title":"Nat Methods"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080576","article-title":"Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity","volume":"36","author":"Fisher","year":"2009","journal-title":"J Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.intimp.2016.05.012","article-title":"The association between reduced folate carrier-1 gene 80G\/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: a meta-analysis","volume":"38","author":"Li","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jbspin.2016.04.013","article-title":"Immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"84","author":"Sigaux","year":"2017","journal-title":"Joint Bone Spine"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.865267","article-title":"Biomarkers to predict DMARDs efficacy and adverse effect in rheumatoid arthritis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226350","article-title":"Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial","volume":"84","author":"Tamai","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15110715","article-title":"Predictive biomarkers of methotrexate treatment response in patients with rheumatoid arthritis: a systematic review","volume":"15","author":"Hassan","year":"2025","journal-title":"Metabolites"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24236","article-title":"Precision medicine with leflunomide: consideration of the DHODH haplotype and plasma teriflunomide concentration and modification of outcomes in patients with rheumatoid arthritis","volume":"73","author":"Wiese","year":"2021","journal-title":"Arthritis Care Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2020-0146","article-title":"Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide","volume":"22","author":"Makarem","year":"2021","journal-title":"Pharmacogenomics"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12760","article-title":"Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis","volume":"81","author":"Hopkins","year":"2016","journal-title":"Brit J Clin Pharma"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.101974","article-title":"Pharmacogenetics of therapies in rheumatoid arthritis: an update","volume":"38","author":"Babiker-Mohamed","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/24.3.269","article-title":"Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy","volume":"24","author":"Pullar","year":"1985","journal-title":"Rheumatology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/25.3.282","article-title":"Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment","volume":"25","author":"Bax","year":"1986","journal-title":"Rheumatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1038\/s41598-020-60467-8","article-title":"The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis","volume":"10","author":"Yee","year":"2020","journal-title":"Sci Rep"},{"key":"B87","article-title":"A study to determine the active moiety of sulphasalazine in rheumatoid arthritis","volume":"13","author":"Neumann","year":"1986","journal-title":"J Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/art.10307","article-title":"Hydroxychloroquine concentration\u2013response relationships in patients with rheumatoid arthritis","volume":"46","author":"Munster","year":"2002","journal-title":"Arthritis Rheumatism"},{"key":"B89","article-title":"Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis--a cross sectional study","volume":"20","author":"Tett","year":"1993","journal-title":"J Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bfopcu.2014.01.002","article-title":"Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients","volume":"52","author":"Mahdy","year":"2014","journal-title":"Bull Fac Pharm Cairo Univ"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.03.018","article-title":"Predictors of treatment response in rheumatoid arthritis","volume":"86","author":"Lequerr\u00e9","year":"2019","journal-title":"Joint Bone Spine"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1461396","article-title":"Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients","volume":"11","author":"Plasencia-Rodr\u00edguez","year":"2024","journal-title":"Front Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002570","article-title":"Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review","volume":"8","author":"Wientjes","year":"2022","journal-title":"RMD Open"},{"key":"B94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13075-016-0995-0","article-title":"Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study","volume":"18","author":"Han","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152740","article-title":"Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges","volume":"73","author":"Avouac","year":"2025","journal-title":"Semin Arthritis Rheumatism"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002432","article-title":"A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis","volume":"3","author":"Owczarczyk","year":"2011","journal-title":"Sci Transl Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214898","article-title":"Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire","volume":"78","author":"Pollastro","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-024-03297-7","article-title":"Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis","volume":"26","author":"Pollastro","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa529","article-title":"Predicting treatment response to IL6R blockers in rheumatoid arthritis","volume":"59","author":"Nouri","year":"2020","journal-title":"Rheumatology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/genes13071284","article-title":"Genetic biomarkers as predictors of response to tocilizumab in rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Janahiraman","year":"2022","journal-title":"Genes"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040220","article-title":"Impact of single-nucleotide polymorphisms of CTLA-4, CD80 and CD86 on the effectiveness of abatacept in patients with rheumatoid arthritis","volume":"10","author":"Marquez Pete","year":"2020","journal-title":"Jpm"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/life11121385","article-title":"Putative association between low baseline gene expression in the peripheral blood and clinical remission in rheumatoid arthritis patients treated with tofacitinib","volume":"11","author":"Tchetina","year":"2021","journal-title":"Life"},{"key":"B103","doi-asserted-by":"publisher","first-page":"21907","DOI":"10.1038\/s41598-020-78925-8","article-title":"Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry","volume":"10","author":"Takahashi","year":"2020","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1689144","article-title":"Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data","volume":"16","author":"Lee","year":"2025","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252697","article-title":"Analyzing biomarker discovery: Estimating the reproducibility of biomarker sets","volume":"17","author":"Forouzandeh","year":"2022","journal-title":"PloS One"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: Statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050995","article-title":"Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: A systematic review","volume":"16","author":"Mucherino","year":"2024","journal-title":"Cancers"},{"key":"B108","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12885-021-08725-4","article-title":"How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review","volume":"21","author":"Seo","year":"2021","journal-title":"BMC Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1177\/1177271920974652","article-title":"Biomarkers: Opportunities and challenges for drug development in the current regulatory landscape","volume":"15","author":"Gromova","year":"2020","journal-title":"biomark Insights"},{"key":"B110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/cts.12865","article-title":"Fit\u2010for\u2010purpose biometric monitoring technologies: Leveraging the laboratory biomarker experience","volume":"14","author":"Godfrey","year":"2021","journal-title":"Clin Trans Sci"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/00045632241285843","article-title":"Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review","volume":"62","author":"Sahin","year":"2025","journal-title":"Ann Clin Biochem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v13i1.6251","article-title":"Biomarkers in clinical practice: opportunities and challenges","volume":"13","author":"Rapp","year":"2024","journal-title":"Mraj"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/wics.1641","article-title":"Biomarker data with measurement error in medical research: A literature review","volume":"16","author":"Wang","year":"2024","journal-title":"Wires Comput Stats"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658970","article-title":"Diagnosis of cancer, autoimmune and infectious diseases and prediction of the therapy effectiveness based on the individual\u2019s immunotype","volume":"16","author":"Tabakov","year":"2025","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09113-7","article-title":"CAR T cell therapy for rheumatoid arthritis","volume":"68","author":"Freeley","year":"2025","journal-title":"Clin Rev Allerg Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803126","article-title":"TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response","volume":"182","author":"Yang","year":"2009","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s42003-022-03050-3","article-title":"Three-dimensional spatial transcriptomics uncovers cell type localizations in the human rheumatoid arthritis synovium","volume":"5","author":"Vickovic","year":"2022","journal-title":"Commun Biol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2020.98431","article-title":"Blood calprotectin in children with juvenile idiopathic arthritis: relationship to flare development after discontinuation of treatment","volume":"58","author":"Boyko","year":"2020","journal-title":"Reumatologia"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091942","article-title":"Role of IL6R genetic variants in predicting response to tocilizumab in patients with rheumatoid arthritis","volume":"14","author":"Sainz","year":"2022","journal-title":"Pharmaceutics"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03373-y","article-title":"Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study","volume":"26","author":"Su","year":"2024","journal-title":"Arthritis Res Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1880487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:45:20Z","timestamp":1784267120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1880487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":120,"alternative-id":["10.3389\/fimmu.2026.1880487"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1880487","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1880487"}}